Focus Partners Advisor Solutions LLC Has $1.41 Million Stake in Illumina, Inc. $ILMN

Focus Partners Advisor Solutions LLC increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 83.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,751 shares of the life sciences company’s stock after acquiring an additional 6,711 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Illumina were worth $1,407,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Illumina by 17.6% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,234,823 shares of the life sciences company’s stock worth $117,814,000 after acquiring an additional 184,620 shares during the period. 180 Wealth Advisors LLC grew its position in Illumina by 8.4% in the second quarter. 180 Wealth Advisors LLC now owns 35,164 shares of the life sciences company’s stock valued at $3,355,000 after purchasing an additional 2,717 shares in the last quarter. Freedom Investment Management Inc. bought a new position in shares of Illumina in the 2nd quarter valued at about $301,000. Ethic Inc. grew its position in shares of Illumina by 23.1% in the 2nd quarter. Ethic Inc. now owns 16,678 shares of the life sciences company’s stock valued at $1,581,000 after acquiring an additional 3,125 shares during the period. Finally, ARK Investment Management LLC grew its position in shares of Illumina by 30.5% in the 2nd quarter. ARK Investment Management LLC now owns 1,168,078 shares of the life sciences company’s stock valued at $111,446,000 after acquiring an additional 272,759 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

NASDAQ ILMN opened at $100.11 on Monday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $15.39 billion, a P/E ratio of 12.67, a P/E/G ratio of 2.47 and a beta of 1.40. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The firm has a 50-day moving average price of $98.17 and a two-hundred day moving average price of $91.76.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on ILMN shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Illumina in a research report on Saturday. Stephens set a $110.00 price objective on shares of Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Scotiabank downgraded shares of Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price objective for the company. in a research report on Friday, July 11th. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a research note on Tuesday, September 2nd. Five equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $115.25.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.